NATC2019

Call for Papers

Designed for experts in pharma and academia, this conference will explore the latest advances in antibody-based therapeutics in oncology. Talks will review the recent developments in bispecific antibody technology, as well as exploring the potential of new antibody and antibody-mimicking formats. A dedicated checkpoint blockades session will also examine new approaches in neutralizing cancer cell immune blockades, including advances in PD1, PD-L1 and CTLA4 targeting therapeutics, and the discovery and targeting of new biomarkers.

With recent breakthroughs in immunotherapeutics, biotherapeutics are set to lead the way in oncology in the coming years. As one of the dominant biologic formats, monoclonal antibodies stand ready to capitalise on this, building on two decades offered of exciting advancements in the treatment of cancer.